Vasseur, Antoine
Cabel, Luc http://orcid.org/0000-0001-5515-9180
Hego, Caroline
Takka, Wissam
Trabelsi Grati, Olfa
Renouf, Benjamin
Lerebours, Florence
Loirat, Delphine
Brain, Etienne http://orcid.org/0000-0003-0881-9371
Cottu, Paul
Sablin, Marie-Paule
Pierga, Jean-Yves
Callens, Céline http://orcid.org/0000-0003-3377-4937
Renault, Shufang http://orcid.org/0000-0001-9234-1002
Bidard, François-Clément http://orcid.org/0000-0001-5932-8949
Funding for this research was provided by:
This work was supported by SIRIC 3 Curie
Article History
Received: 11 September 2023
Revised: 15 February 2024
Accepted: 16 February 2024
First Online: 27 February 2024
Competing interests
: This work was supported by SIRIC 3 Curie (grant INCa-DGOS-INSERM-ITMO Cancer_18000). FC Bidard received research support and honoraria for advisory board from AstraZeneca and Novartis. F Lerebours reports consulting for AstraZeneca, Eisai, Genomic Health, Eli Lilly, Laboratories Pierre Fabre, and Roche; and travel support from AstraZeneca, Eisai, Novartis, Pfizer, Roche, and Laboratories Pierre Fabre; and lecture fees from AstraZeneca, Eisai, Eli Lilly, Novartis, and Laboratories Pierre Fabre. MP Sablin reports lecture fees from Servier. JY Pierga reports consulting for AstraZeneca, Eisai, Eli Lilly, MSD, Gilead, Daiichy Sankyo, Novartis, Pfizer and travel support from AstraZeneca, MSD, Novartis, Pfizer, Gilead, Seagen, and lecture fees from AstraZeneca, MSD, Eli Lilly, Novartis, Gilead, Veracyte. No other potential conflicts of interest were reported.